Table 6.
Arterial overcrossing (32 eyes) | Venous overcrossing (23 eyes) | P value | |
---|---|---|---|
Baseline examinations | |||
LogMAR visual acuity | 0.34 ± 0.23 | 0.24 ± 0.29 | 0.158 |
Foveal thickness (μm) | 516.3 ± 157.9 | 498.4 ± 146.8 | 0.380 |
Total NPA (disc area) | 7.06 ± 12.1 | 21.5 ± 18.6 | 0.002 |
Total NPA (disc area, only major BRVO) | 14.8 ± 15.6 (12 eyes) | 26.9 ± 17.5 (19 eyes) | 0.064 |
Macular NPA in SCP (mm2) | 1.50 ± 0.42 | 1.60 ± 0.73 | 0.656 |
Macular NPA in DCP (mm2) | 1.75 ± 0.53 | 1.75 ± 0.88 | 0.991 |
12-months after initial treatment | |||
LogMAR visual acuity | 0.05 ± 0.14 | 0.02 ± 0.18 | 0.607 |
Total NPA (disc area) | 16.7 ± 25.6 | 44.8 ± 29.2 | 0.002 |
Total NPA (disc area, only major BRVO) | 34.7 ± 27.8 (12 eyes) | 55.3 ± 22.1 (19 eyes) | 0.047 |
Central macular NPA in SCP (mm2) | 1.41 ± 0.47 | 1.71 ± 0.61 | 0.110 |
Central macular NPA in DCP (mm2) | 1.59 ± 0.56 | 1.94 ± 0.69 | 0.090 |
24-months after initial treatment | |||
LogMAR visual acuity | 0.05 ± 0.13 | 0.01 ± 0.21 | 0.469 |
Central macular NPA in SCP (mm2) | 1.36 ± 0.41 | 1.59 ± 0.64 | 0.197 |
Central macular NPA in DCP (mm2) | 1.67 ± 0.42 | 1.81 ± 0.66 | 0.449 |
Number of IVR for 24-months | 5.6 ± 2.3 | 4.9 ± 2.4 | 0.269 |
Occurrence of neovascular changes | 0 (0%) | 6 (31.6%) | 0.030 |
Data are mean ± standard deviation unless otherwise indicated; The analyses of total NPA, neovascular complications were examined after exclusion of eyes with macular branch retinal vein occlusion; logMAR = logarithm of the minimum angle of resolution; NPA = retinal nonperfusion area. SCP = superficial capillary plexus; DCP = deep capillary plexus; IVR = intravitreal ranibizumab injections; Total NPAs were separately indicated in all patients, and in patients with major BRVO; The baseline measurements of optical coherence tomography angiography were obtained after the initial resolution of macular edema and macular hemorrhage.